Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule drugs that target the A3 adenosine receptor (A3AR). The company operates within the biotechnology and pharmaceutical industries, with a therapeutic focus on inflammatory diseases and oncology, particularly conditions with significant unmet medical need. Its drug development strategy is centered on leveraging the overexpression of A3AR in pathological cells to achieve selective therapeutic effects.
The company’s primary product candidates include Piclidenoson (CF101) for autoimmune and inflammatory indications such as psoriasis and rheumatoid arthritis, and Namodenoson (CF102) for liver-related diseases, including hepatocellular carcinoma (HCC) and non-alcoholic steatohepatitis (NASH). Can-Fite was founded in 1994 and is headquartered in Israel. Over time, it evolved from early-stage receptor research into a publicly traded clinical-stage company listed on NASDAQ and the Tel Aviv Stock Exchange, advancing multiple compounds through mid- to late-stage clinical development.
Business Operations
Can-Fite’s operations are organized around its core drug development programs targeting A3AR. The company generates value primarily through the advancement of its proprietary drug candidates through clinical trials, with the objective of regulatory approval and potential commercialization through partnerships or licensing arrangements. Its key operating focus is on clinical research and development, including Phase II and Phase III clinical studies conducted in compliance with U.S. FDA and international regulatory standards.
The company conducts no large-scale commercial manufacturing and relies on external contract research organizations (CROs) and manufacturing partners for clinical trial execution and drug production. Operations are primarily research-driven, with clinical trials conducted in the United States, Europe, and Israel. Information regarding material subsidiaries or joint ventures is limited; data inconclusive based on available public sources regarding any revenue-generating subsidiaries or long-term commercial partnerships currently contributing material revenue.
Strategic Position & Investments
Strategically, Can-Fite positions itself as a niche innovator in receptor-specific therapeutics, focusing on diseases where A3AR biology is well validated. Its growth strategy centers on advancing Piclidenoson and Namodenoson through late-stage clinical trials, seeking regulatory approvals, and entering regional or global licensing agreements to support commercialization. The company has publicly emphasized capital-efficient development and targeted indications with clearer regulatory pathways.
Major investments are concentrated in clinical trial programs rather than acquisitions. While Can-Fite has announced collaborations and regional licensing discussions over time, publicly available information does not consistently confirm long-term, revenue-producing partnerships; data inconclusive based on available public sources. The company’s emerging focus includes expanding the clinical applicability of A3AR agonists in oncology and chronic liver diseases.
Geographic Footprint
Can-Fite BioPharma is headquartered in Petah Tikva, Israel, which serves as the center for executive management and research oversight. The company maintains a global operational footprint primarily through its clinical development activities rather than physical offices or manufacturing facilities.
Its market and research presence spans North America, Europe, and the Middle East, driven by multinational clinical trials and regulatory interactions. The company’s shares trade publicly in the United States and Israel, providing it with access to international capital markets and investors. Beyond clinical trial sites and regulatory engagement, there is limited evidence of permanent operational infrastructure outside Israel.
Leadership & Governance
Can-Fite was founded by Pnina Fishman, who continues to play a central role in shaping the company’s scientific and strategic direction. Leadership emphasizes a research-driven philosophy focused on mechanistic validation, disciplined clinical development, and long-term value creation through intellectual property and regulatory progress.
Key executives include:
- Pnina Fishman – Founder, Chief Executive Officer and Chief Scientific Officer
- Irit Horesh – Chief Financial Officer (role reported in public company disclosures; tenure details vary across sources)
- Eli Dagan – Chairman of the Board (board leadership information reported; operational involvement limited)
Information on additional executive leadership and governance committee structure is limited and, in some cases, inconsistent across public disclosures; data inconclusive based on available public sources.